Navigation Links
Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
Date:10/1/2007

p>Dr. Davis commented, "The potential for the novel claim for MOTN dosing could reduce some of the lingering stigma attached to taking a sleep medication, and perhaps help accelerate growth in the prescription market to a level more consistent with the historical and emerging epidemiological studies that suggest a high prevalence of MOTN insomnia in the US population."

About Intermezzo(TM)

Intermezzo(TM) (zolpidem tartrate lozenge) is a low dose formulation of zolpidem that is currently in late phase 3 clinical trials for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Formulated as a sublingual tablet that dissolves under the tongue, Intermezzo(TM) employs Transcept's Bimucoral(TM) technology to accelerate bioavailability. The company intends to file the Intermezzo(TM) NDA with the US Food and Drug Administration (FDA) in 2008.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product, Intermezzo(TM) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem that is currently in late phase 3 clinical trials for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Another product being developed by Transcept is TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. TO-2060 is currently the subject of an initial proof of concept trial in the treatment of alcohol use disorder. For more information, please visit the Company's website at: http://www.transcept.com.


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Bruker Participates in Dutch Funded Super Microscope Project
4. Venture Investors early-stage fund grows to $115 million
5. Investor warns of angel-venture funding gap
6. Brazilian bio-industry should impress American investors
7. Investors raise $25 million for biodiesel plant
8. Bio-energy and cleantech grab attention of investors
9. Venture Investors to open Michigan office
10. Early-stage executives hear from investors
11. Commerce qualifies seven for investor tax credits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 , Not ... in, into or from any jurisdiction where to do so ... jurisdiction.  Shire plc ("Shire" or the "Company") (LSE: ... this afternoon.  Shire confirms it has held a meeting with ... by Shire without the prior agreement or approval of AbbVie. ...
(Date:7/11/2014)... Research ( http://www.bccresearch.com ) reveals in its new report, ... MARKETS , the global market for digital polymerase chain ... This is estimated to grow to $490 billion in ... of 28.6%. , New digital PCR technology has created ... broader PCR field. The opportunities presented by this technology ...
(Date:7/11/2014)... MISSISSAUGA, ON , July 11, 2014 /CNW/ - ... Canada approved APTIOM TM (eslicarbazepine acetate) for use ... partial-onset seizures in patients with epilepsy who are not ... not indicated for use in patients under 18 years ... the most common neurological disorders and according to Epilepsy ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Cayenne ... company specializing in the soft tissue reconstruction segment, ... Anchor System for surgeries involving the shoulder and ... through a novel, inserter-controlled deployment method. The unique ... partial deployment, anchor pull-out, or anchor displacement (also ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3
... ... ... PRXL ), a leading global biopharmaceutical services,organization, today announced the ... technology organization. By combining,ClinPhone with Perceptive Informatics, PAREXEL,s wholly-owned technology,subsidiary, ...
... p.m. ET Today -, SUNNYVALE, Calif., Aug. 14 ... its fourth quarter,and fiscal year ended June 30, 2008. The ... million, or $0.18 per share, compared to a net loss ... of fiscal 2007., Total operating expenses were $4.8 million ...
... aerospace and ocean engineering at Virginia Tech, has received ... Junior Faculty Award. The award will support Philen,s research ... material and structural systems that have the unique ability ... these innovative materials will lead to new and exciting ...
Cached Biology Technology:PAREXEL Closes the Acquisition of ClinPhone 2PAREXEL Closes the Acquisition of ClinPhone 3PAREXEL Closes the Acquisition of ClinPhone 4PAREXEL Closes the Acquisition of ClinPhone 5Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 2Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 3Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 4Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 5Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results 6
(Date:7/11/2014)... creating a new professorship in tissue engineering to ... Molecular Engineering and the Marine Biological Laboratory, supported ... and Eugene Bell Foundation., The Eugene Bell Professorship ... for Molecular Engineering. That endowed chair holder also ... Eugene Bell Center for Regenerative Biology and Tissue ...
(Date:7/11/2014)... National Institute of Standards and Technology (NIST) need ... effectively, they often prove that necessity is truly ... recently for M. Lorna De Leoz and Stephen ... of glycomics. Glycomics is the study of the ... attached to proteins and lipids and influence cellular ...
(Date:7/11/2014)... relationships with other group members to reduce aggression and ... the strategy for grooming activities shows a certain pattern ... the scientific journal Biology Letters . , Grooming ... practiced without ulterior motives. To be groomed has hygienic ... grooming another individual can provide access to infants, mating ...
Breaking Biology News(10 mins):New professorship in tissue engineering links molecular engineering, marine biology 2Baboons groom early in the day to get benefits later 2
... 14, 2011In a letter to Maine,s two Senators, Susan Collins ... Broihier, MS, RD., said, "I would like to thank you ... that,s particularly important to our statethe amount of potatoes and ... lunch program. Broihier wrote, "First, there is no question ...
... the palo verde, mesquite and acacia trees throughout the Southwestern ... survival of their offspring against the parasitic wasp species that ... are the seed beetles Mimosestes amicus , living all ... all but invisible to our eyes or nearly so. ...
... 14, 2011 As the United States nears another ... (BGU) have determined scientifically, for the first time, that ... According to Prof. Hagit Cohen from the Anxiety ... Sciences, "We understand that emotional changes are related and ...
Cached Biology News:This beetle uses eggs as shields against wasps 2This beetle uses eggs as shields against wasps 3This beetle uses eggs as shields against wasps 4This beetle uses eggs as shields against wasps 5Voting causes stress according to Ben-Gurion University of the Negev study 2
CELLine System cultivation flask (for secreted products)...
... StabilCoat Plus Microsphere/Microarray Stabilizer is an aqueous ... and other non-toxic chemicals in a PBS ... 7.4. This product contains a combination ... a preservative. StabilCoat Plus Stabilizer provides ...
... The mini incubation trays are ... to screen antigens that have ... Each tray has eight 10.5 ... that accommodate strips cut from ...
... designed for quick and easy protein purification ... two 0.25mm holes laser cut at the ... remain liquid-tight during incubation of the gel ... protein diffuses from the gel into the ...
Biology Products: